Haushabhau S Pagire, Suvarna H Pagire, Byung-Kwan Jeong, Won-Il Choi, Chang Joo Oh, Chae Won Lim, Minhee Kim, Jihyeon Yoon, Seong Soon Kim, Myung Ae Bae, Jae-Han Jeon, Sungmin Song, Hee Jong Lee, Eun Young Lee, Peter C Goughnour, Dooseop Kim, In-Kyu Lee, Rohit Loomba, Hail Kim, Jin Hee Ahn
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is currently the leading cause of chronic liver disease worldwide. Metabolic Dysfunction-Associated Steatohepatitis (MASH), an advanced form of MASLD, can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Based on recent findings by our team that liver 5HT2A knockout male mice suppressed steatosis and reduced fibrosis-related gene expression, we developed a peripheral 5HT2A antagonist, compound 11c for MASH. It shows good in vitro activity, stability, and in vivo pharmacokinetics (PK) in rats and dogs...
January 20, 2024: Nature Communications